Psychiatrist.comAssociation of Selective Serotonin Reuptake Inhibitor and Other Antidepressant Drugs With Dental Implant Failure

Two meta-analyses and a 2025 cohort study consistently show antidepressant users face 2-3x higher dental implant failure rates than nonusers. At the patient level, failure occurred in 6%-23% of antidepressant users vs. 2%-8% of nonusers. Methodological limits preclude causal inference, but the association is clinically significant as a risk marker regardless of mechanism.

Clinical Considerations

• Unadjusted implant failure risk more than doubled in antidepressant users across studies; SSRI users in one cohort showed 18.6% vs. 6.7% patient-level failure rates
• Depression itself contributes behavioral and biological risk factors for bone disease, complicating separation of drug effect from disease effect
• A meta-analysis of RCTs found fluoxetine and citalopram associated with doubled fracture risk after 6 months, suggesting a possible direct bone mechanism
• Stopping antidepressants pre-implant is not supported; washout timeline for any bone-related mechanism is unknown and relapse risk remains

Practice Applications

• Counsel patients on elevated implant failure risk before dental implant procedures
• Evaluate and address modifiable implant failure risk factors (smoking, diabetes, bisphosphonate use, alcohol use) in antidepressant-treated patients
• Coordinate with dental providers to flag antidepressant use as a risk variable at implant planning
• Monitor patients post-implant for early signs of osseointegration failure

More on Antidepressants